Plasma albumin and platelet function: relevance to atherogenesis and thrombosis

References

• Porcellati S, Gresele P, Stasi M, et al. Albumin prevents TXB, formation from thrombin-stimulated human platelets by sequestering the liberated arachidonic acid in the extracellular space. Platelets 1995; 6: 381–7
   PubMed Web of Science ®Google Scholar
• Al-Mugeirin M M, Gader A M A, Al-Rasheed S A, Bahakim H M, Al-Momen A K, Al-Salloum A. Platelet aggregometry – dose related responses to arachidonic acid in childhood nephrotic syndrome. Platelets 1995; 6: 71–4
   PubMedGoogle Scholar
• Phillips A N, Shaper A G, Whincup P H. Association between serum albumin and mortality from cardiovascular disease, cancer and other causes. Lancer 1989; ii: 1434–6
   Google Scholar
• Kuller L H, Eichner J E, Orchard T J, Grandits G A, McCallum L, Tracy R P. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1991; 134: 1266–77
   PubMed Web of Science ®Google Scholar
• Purdon A D, Rao A K. Interaction of albumin, arachidonic acid and prostanoids in platelets. Prostagl Leukotr Essntl Fatty Acids: Revs 1989; 35: 213–8
   PubMed Web of Science ®Google Scholar
• Rao A K, Koike K, Day H J, Smith J B, Holmsen H. Bleeding disorder associated with albumin-dependent partial deficiency in platelet thromboxane production. Am J Clin Pathol 1985; 83: 687–96
   PubMedGoogle Scholar
• Hornberger W, Patscheke H. Transient concentrations and agonist potency of PGH, in platelet activation by endogenous arachidonate. Eicosanoids 1989; 2: 241–8
   PubMedGoogle Scholar
• Gresele P, Deckmyn H, Huybrechts E, Vermylen J. Serum albumin enhances the impairment of platelet aggregation with thromboxane synthase inhibition by increasing the formation of prostaglandin D. Biochem Pharmacol 1984; 33: 2083–8
   PubMed Web of Science ®Google Scholar
• Guichardant M, Petit F, Lagarde M. Metabolism of endogenous arachidonic acid in weakly activated platelets. Absence of leukocyte cooperative products in whole blood. Eicosanoids 1989; 2: 117–21
   PubMedGoogle Scholar
• Peplow P V, Mikhailidis D P. Platelet activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism. Prostagl Leukotr Essntl Fatty Acids 1990; 41: 71–82
   PubMed Web of Science ®Google Scholar
• Tokomura A, Yoshida J, Maruyama T, Fukuzawa K, Tsukatani H. Platelet aggregation induced by ether-linked phospholipids. I. Inhibitory actions of bovine serum albumin and structural analogues of platelet activating factor. Thromb Res 1987; 46: 51–63
   PubMedGoogle Scholar
• Colli S, Maderna P, Caruso D, Stragliotto E, Galli G, Tremoli E. Albumin interferes with arachidonate metabolism in platelets and neutrophils. Eicosanoids 1989; 2: 51–7
   PubMedGoogle Scholar
• Fitzgerald G A, Brash A R, Oaks J A, Pedersen A K. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest 1983; 72: 1336–43
   PubMed Web of Science ®Google Scholar
• Doweiko J P, Bistrian B R. The effect of glycosylated albumin on platelet aggregation. J Parenteral Enteral Nutrn 1994; 18: 516–20
   PubMed Web of Science ®Google Scholar
• Surya I I, Gorter G, Akkerman J W. Arachidonate transfer between platelets and lipoproteins. Thromb Haemostas 1992; 68: 719–26
   PubMed Web of Science ®Google Scholar
• Mikhailidis D P, Mikhailidis A M, Dandona P. Effect of human plasma proteins on stabilisation of platelet anti-aggregatory activity of prostacyclin. Ann Clin Biochem 1982; 19: 241–4
   PubMed Web of Science ®Google Scholar
• Mikhailidis D P, Mikhailidis A M, Bmadas M A, Dandona P. Effect of non-esterified fatty acids on the stability of prostacyclin activity. Metabolism 1983; 32: 717–21
   PubMedGoogle Scholar
• Goodnight S H, Inkeles S B, Kovach N L, Connor W E. Reduced prostacyclin survival after fasting-induced elevation of plasma fatty acids. Thromb Haemostas 1985; 54: 418–21
   PubMedGoogle Scholar
• Bakker W W, Poelstra K, Barradas M A, Mikhailidis D P. Platelets and ectonucleotidases. Platelets 1994; 5: 121–9
   PubMed Web of Science ®Google Scholar
• Barradas M A, Mikhailidis D P, Dandona P. The effect of non-esterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract 1987; 3: 9–19
   PubMedGoogle Scholar
• Mikhailidis D P, Barradas M A, Maris A, Jeremy J Y, Dandona P. Fibrinogen mediated activation of platelet aggregation and thromboxane A release: implications in vascular disease. J Clin Pathol 1985; 38: 1166–71
   PubMed Web of Science ®Google Scholar
• Goubran F, Maklady F. In vivo platelet activity and serum albumin concentration in nephrotic syndrome. Blut 1988; 57: 15–17
   PubMedGoogle Scholar
• Bennett A, Cameron J S. Platelet hyperaggregability in the nephrotic syndrome which is not dependent on arachidonic acid metabolism or on plasma albumin concentration. Clin Nephrol 1987; 27: 182–8
   PubMed Web of Science ®Google Scholar
• Jackson C A, Greaves M, Patterson A D, Brown C B, Preston F E. Relationship between platelet aggregation, thromboxane synthesis and albumin concentration in nephrotic syndrome. Br J Haematol 1982; 52: 69–77
   PubMed Web of Science ®Google Scholar
• Vaziri N D, Gonzales E C, Shayestehfar B, Barton C H. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J Lab Clin Med 1994; 124: 118–24
   PubMedGoogle Scholar
• Schieppati A, Dodesini P, Benigni A, et al. The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney Intnl 1984; 25: 671–6
   PubMedGoogle Scholar
• Kuhlmann U, Steurer J, Rhyner K, von Felten A, Briner J, Siegenthaler W. Platelet aggregation and beta-thromboglobulin levels in nephrotic patients with and without thrombosis. Clin Nephrol 1981; 15: 229–35
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Mecca G, Marchesi D, et al. Platelet hyperaggregability and the nephrotic syndrome. Thromb Res 1979; 16: 345–54
   PubMed Web of Science ®Google Scholar
• Stuart M, Spitzer R E, Nelson D A, Sills R H. Nephrotic Syndrome: increased platelet prostaglandin formation, hyperaggregability, and reduced platelet life span. Pediatr Res 1980; 14: 1078–81
   PubMedGoogle Scholar
• Machleidt C, Mettang T, Starz E, Weber J, Risler T, Kuhlmann U. Multifactorial genesis of enhanced platelet aggregability in patients with nephrotic syndrome. Kidney Intnl 1989; 36: 1119–24
   PubMed Web of Science ®Google Scholar
• Ernst E, Resch K L. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J 1995; 16(Suppl. A)47–53
   PubMedGoogle Scholar
• Koenig W. Recent progress in the clinical aspects of fibrinogen. Eur Heart J 1995; 16(Suppl. A)54–9
   PubMedGoogle Scholar
• Thaulow E, Erikssen J, Sandvik L, Storkmoren H, et al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613–7
   PubMed Web of Science ®Google Scholar
• Russi G, Weigand K. Analbuminemia. Klin Woschenschrift 1983; 61: 541–5
   PubMedGoogle Scholar
• Baldo G, Fellin R, Manzato E, et al. Characterization of hyperlipidemia in two patients with analbuminemia. Clin Chim Acta 1983; 128: 307–19
   PubMedGoogle Scholar
• Frohlich J, Pudek M R, Cormode E J, Sellers E M, Abel J G. Further studies on plasma proteins, lipids, and dye-and-drug-binding in a child with analbuminemia. Clin Chem 1981; 27: 1213–6
   PubMedGoogle Scholar
• Stewart M W, Laker M F, Alberti K G. The contribution of lipids to coronary heart disease in diabetes mellitus. J Intern Med (Suppl) 1994; 736: 41–6
   PubMedGoogle Scholar
• Reinila A. Long-term effects of untreated diabetes on the arterial wall in rat. Diabetologia 1981; 20: 205–12
   PubMedGoogle Scholar
• Thompson C S, Strong P, Mikhailidis D P. Improvement of ketoacidosis in the diabetic rat after the administration of the oral antilipolytic agent GR 79236. Clin Sci 1994; 86: 593–8
   PubMed Web of Science ®Google Scholar
• Tietz N W, Finley P R. Clinical Guide to Laboratory Tests. WB Saunders, Philadelphia 1983; 17
   Google Scholar
• Gruden G, Cavallo-Perin P, Romagnoli R, Ruiu G, Pagano G. Plasma beta-thromboglobulin and platelet factor 4 are not increased in insulin-dependent diabetic patients with micro-albuminuria. Acta Diabetol 1994; 31: 130–2
   PubMedGoogle Scholar
• Baba T, Kodama T, Yasuda T K, Ishizaki T. Comparison of platelet aggregability in Japanese type 2 diabetic patients with and without microalbuminuria. Diabetic Med 1993; 10: 643–6
   PubMedGoogle Scholar
• Feskens E J M, Kromhout D. Hyperinsulinaemia, risk factors, and coronary heart disease. The Zutphen elderly study. Arterioscler Thromb 1994; 14: 1641–7
   PubMedGoogle Scholar
• Jeremy J Y, Mikhailidis D P, Dandona P. Simulating the diabetic environment modifies in vitro prostacyclin synthesis. Diabetes 1983; 32: 217–21
   PubMedGoogle Scholar
• Glassman A B. Platelet abnormalities in diabetes mellitus. Ann Clin Lab Sci 1993; 23: 47–50
   PubMed Web of Science ®Google Scholar
• The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86
   PubMed Web of Science ®Google Scholar
• Jeremy J Y, Mikhailidis D P, Pittilo R M. Cigarette smoking and cardiovascular disease. J Royal Soc Health 1995; 115: 289–95
   PubMedGoogle Scholar
• Mikhailidis D P, Barradas M A, Jeremy J Y, Dandona P. Cigarette smoking inhibits prostacyclin formation. Lancet 1983; ii: 627–8
   Google Scholar
• Margetts B, Jackson A. Interactions between people's diet and their smoking habits: the dietary and nutritional survey of British adults. Br Med J 1993; 307: 1381–4
   PubMed Web of Science ®Google Scholar
• Midgette A S, Baron J A, Rohan T E. Do cigarette smokers have diets that increase the risk of coronary heart disease and cancer?. Am J Epidemiol 1993; 137: 521–9
   PubMed Web of Science ®Google Scholar
• Musabayane C T, Ndhlovu C E, Bwititi P, Msamati B C. Serum albumin concentrations in rural Zimbabweans. Centr African J Med 1995; 41: 204–8
   PubMedGoogle Scholar
• Myers L A, Boyce J T, Robison R L. The tolerability and pharmacology of interleukin-6 administered in combination with GM-CSF or G-CSF in the rhesus monkey. Toxicology 1995; 101: 157–66
   PubMedGoogle Scholar
• Yanagawa H, Sone S, Takahashi Y, et al. Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer 1995; 71: 1095–8
   PubMed Web of Science ®Google Scholar
• Burstein S A, Downs T, Friese P, et al. Thrombocytopoiesis in normal and sublethally irradiated dogs: response to human interleukin-6. Blood 1992; 80: 420–8
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Speroff T, Ganapathi M K, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991; 146: 3032–7
   PubMed Web of Science ®Google Scholar
• Hoak J C. Stearic acid, clotting, and thrombosis. Am J Clin Nutr 1994; 60(Suppl. 6)1050S–3S
   Google Scholar
• Mikhailidis D P, Winder A F. A place for fibrinogen-lowering drugs in cardiovascular disease?. J Drug Develop Clin Pract 1995; 7: 3–5
   Google Scholar
• Ueda N. Effect of corticosteroids on some hemostatic parameters in children with minimal change nephrotic syndrome. Nephron 1990; 56: 374–8
   PubMed Web of Science ®Google Scholar
• Hoyer P F, Gonda S, Barthels M, Krohn H P, Brodehl J. Thromboembolic complications in children with nephrotic syndrome. Risk and incidence. Acta Paediatr Scand 1986; 75: 804–10
   PubMedGoogle Scholar
• Iioka Y, Kikuchi K, Tada H, Isogai S, Urayama T. Plasma soluble fibrin monomer complexes in nephrotic syndrome – with reference to hypoalbuminemia. Tohuku J Exper Med 1984; 143: 53–7
   PubMedGoogle Scholar
• Barradas M A, Mikhailidis D P, Phillips A N, Shaper A G. Albumin, haemostasis and cardiovascular disease. Fibrinolysis 1991; 5: 131
   Google Scholar
• Delvos U, Preissner K T, Muller-Berghaus G. Binding of fibrinogen to cultured bovine endothelial cells. Thromb Haemostas 1985; 53: 26–31
   PubMedGoogle Scholar
• George J N. Platelet IgG: measurement, interpretation, and clinical significance. Progr Haemostas Thromb 1991; 10: 97–126
   PubMedGoogle Scholar
• Coller B S, Seligsohn U, West S M, Scudder L E, Norton K J. Platelet fibrinogen and vitronectin in Glanzmann thrombasthenia. Blood 1991; 78: 2603–10
   PubMed Web of Science ®Google Scholar
• Hotchkiss A J, Leissinger C A, Smith M E, Jordan J V, Kautz C A, Shulman N R. Evaluation by quantitative acid elution and radioimmunoassay of multiple classes of immunoglobulins and serum albumin associated with platelets in idiopathic thrombocytopenic purpura. Blood 1986; 67: 1126–3I
   PubMedGoogle Scholar
• Thorne S A, Abbot S E, Winyard P G, Blake D R, Mills P G. Extent of oxidative modification of low density lipoprotein determines the degree of cytotoxicity to human coronary artery cells. Heart 1996; 75: 11–16, (Abstr.).
   PubMedGoogle Scholar
• Miller Y J, Felikman Y, Shaklai N. The involvement of low-density lipoprotein in hemia transport potentiates peroxidative damage. Biochim Biophys Acta 1995; 1272: 119–27
   PubMed Web of Science ®Google Scholar
• McDowell I F, McEnemy J, Trimble E R. A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. Ann Clin Biochem 1995; 32: 167–74
   PubMed Web of Science ®Google Scholar
• Luoma P V, Nayha S, Sikkila K, Hassi J. High serum alpha-tocopherol, albumin, selenium and cholesterol, and low mortality from coronary heart disease in northern Finland. J Intern Med 1995; 237: 49–54
   PubMed Web of Science ®Google Scholar
• Asayama K, Uchida N, Nakane T, et al. Antioxidants in the serum of children with insulin-dependent diabetes mellitus. Free Radical Biol Med 1993; 15: 597–602
   PubMed Web of Science ®Google Scholar
• Hu M L, Louie S, Cross C E, Motchnik P, Halliwell B. Anti-oxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993; 121: 257–62
   PubMed Web of Science ®Google Scholar
• Strubelt O, Younes M, Li Y. Protection by albumin against ischaemia- and hypoxia-induced hepatic injury. Pharmacol Toxicol 1994; 75: 280–4
   Google Scholar
• Silverman L M, Christenson R H, Grant G H. Textbook of Clinical Chemistry, N W Tietz. WB Saunders, Philadelphia 1986; 587–9
   Google Scholar
• Schwertner H A, Jackson W C, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994; 40: 18–23
   PubMed Web of Science ®Google Scholar
• Breimer L H, Spyropoulos K A, Winder A F, Mikhailidis D P, Hamilton G. Is bilirubin protective against coronary artery disease?. Clin Chem 1994; 40: 1987–8
   PubMedGoogle Scholar
• Breimer L H, Wannamethee G, Ebrahim S, Shaper A G. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995; 41: 1504–8
   PubMed Web of Science ®Google Scholar
• McPherson R A. Clinical Diagnosis and Management by Laboratory Methods, J B Henry. WB Saunders., Philadelphia 1991; 215: 28
   Google Scholar
• Stocker R, Glazer A N, Ames B N. Antioxidant activity of albumin-bound bilirubin. PNAS 1987; 84: 5918–22
   PubMed Web of Science ®Google Scholar
• Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994; 269: 16712–9
   PubMed Web of Science ®Google Scholar
• Wu T W, Wu J, Li R K, Mickle D, Carey D. Albumin-bound bilürubins protect human ventricular myocytes against oxyradical damage. Biochem Cell Biol 1991; 69: 683–8
   PubMed Web of Science ®Google Scholar
• Neuzil J, Stocker R. Bilirubin attenuates radical-mediated damage to serum albumin. FEBBS Lett 1993; 331: 281–4
   PubMedGoogle Scholar
• Kaapa P. Immunoreactive thromboxane 82 and 6-keto-prostaglandin F1 alpha in neonatal hyperbilirubinemia. Prostagl Leukotr Med 1985; 17: 97–105
   PubMedGoogle Scholar
• Dahlen G H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111–26
   PubMed Web of Science ®Google Scholar
• Hong S Y, Yang D H. Lipoprotein (a) levels and fibrinolytic activity in patients with nephrotic syndrome. Nephron 1995; 69: 125–30, (Abstr.).
   PubMedGoogle Scholar
• Gansevoort R T, Heeg J E, Dikkeschei F D, de Zeeuw D, de Jong P E, Dullaart R P. Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria. Nephrol Dial Transplant 1994; 9: 244–50
   PubMedGoogle Scholar
• Kanno H, Saito E, Fujioka T, Yasugi T. Lipoprotein (a) levels in the nephrotic syndrome. Intern Med 1992; 31: 1004–8
   PubMedGoogle Scholar
• Malle E, Ibovnik A, Stienmetz A, Kostner G M, Sattler W. Identification of glycoprotein IIb as the lipoprotein (a)-binding protein on platelets. Arteriosclerosis 1994; 14: 345–52
   Google Scholar
• Ezratty A, Simon D I, Loscalzo J. Lipoprotein (a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 1993; 32: 4628–33
   PubMed Web of Science ®Google Scholar
• Malle E, Sattler W, Prenner E, Leis H J, Hermetter A, Cries A, Kostner G M. Effects of dietary fish oil supplementation on platelet aggregability and platelet membrane fluidity in normolipemic subjects with and without high plasma lipoprotein (a) concentrations. Atherosclerosis 1991; 88: 193–201, (Abstr.).
   PubMed Web of Science ®Google Scholar
• Mikhailidis D P, Spyropoulos K A, Jagroop I A, Byrne D J, Vallance D T, Winder A F. Lipoprotein (a) and fibrinogen: relationships in a cardiovascular risk management clinic. Atherosclerosis 1995; 115(Suppl.)S91
   Google Scholar
• Folsom A R, Wu K K, Davis C E, Conlan M G, Sorlie P D, Szklo M. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191–205
   PubMed Web of Science ®Google Scholar
• Mikhailidis D P, Fonseca V A, Barradas M A, Jeremy J Y, Dandona P. Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparnoid (Org 10172). Br J Clin Pharmacol 1987; 24: 415–24, (Abstr.).
   PubMed Web of Science ®Google Scholar
• Jagroop I A, Barradas M A, Mikhailidis D P. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin-induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996; 41: 163–5
   PubMed Web of Science ®Google Scholar
• Mikhailidis D P, Hutton R A, Jeremy J Y, Dandona P. Hypothermia and pancreatitis. J Clin Pathol 1983; 36: 483–4
   PubMed Web of Science ®Google Scholar
• Jensen J S. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1324–9
   PubMed Web of Science ®Google Scholar
• McCandless B K, Powers M R, Cooper J A, Malik A B. Effect of albumin on hydraulic conductivity of pulmonary artery endothelial monolayers. Am J Physiol 1991; 260: L571–6
   PubMed Web of Science ®Google Scholar
• Salive M E, Cornoni-Huntley J, Phillips C L, et al. Serum albumin in older persons: relationship with age and health status. J Clin Epidemiol 1992; 45: 213–21
   PubMed Web of Science ®Google Scholar
• Klonoff-Cohen H, Barrett-Connor E L, Edelstein S L. Albumin levels as a predictor of mortality in the healthy elderly. J Clin Epidemiol 1992; 45: 207–12
   PubMed Web of Science ®Google Scholar
• Hu H, Sparrow D, Weiss S. Association of serum albumin with blood pressure in the normative aging study. Am J Epidemiol 1992; 136: 1465–73
   PubMed Web of Science ®Google Scholar
• Cederblad G, Korsan-Bengsten K. Effect of clofibrate on plasma proteins including components of the hemostatic mechanism. Clin Chim Acta 1976; 66: 9–17
   PubMedGoogle Scholar
• Caimi G, Francavilla G, Romano A, Catania C, Santonocito G, Sarno A. Blood rheology changes during bezafibrate treatment. Br J Clin Pract 1988; 42: 456–8
   PubMedGoogle Scholar
• Mathur S, Barradas M A, Mikhailidis D P, et al. The effects of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study. Diabetes Res 1990; 14: 133–8
   PubMedGoogle Scholar
• Mulvihill J N, Faradji A, Oberling F, Cazenave J P. Surface passivation by human albumin of plasmapheresis circuits reduces platelet accumulation and thrombus formation. Experimental and clinical studies. J Biomed Materials Res 1990; 24: 155–63
   PubMed Web of Science ®Google Scholar
• Kottke-Marchant K, Anderson J M, Umemura Y, Marchant R E. Effect of albumin coating on the in vitro blood compatibility of Dacron arterial prosthesis. Biomaterials 1989; 10: 147–55
   PubMed Web of Science ®Google Scholar
• Chandy T, Sharma C P. The antithrombotic effect of prostaglandin El immobilized on albuminated polymer matrix. J Biomed Materials Res 1984; 18: 1115–24
   PubMedGoogle Scholar
• Bellavite P, Andrioli G, Guzzo P, et al. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Analyt Biochem 1994; 216: 444–50
   PubMed Web of Science ®Google Scholar
• Freedman J E, Frei B, Welch G N, Loscalzo J. Glutathione peroxidase potentiates the inhibition of platelet function by S-nitrosothiols. J Clin Invest 1995; 96: 394–400
   PubMed Web of Science ®Google Scholar
• Amano M, Takahasbi M, Kosaka T, Kinoshita M. Differential inhibition of platelet aggregation and calcium mobilization by nitroglycerin and stabilized nitric oxide. J Cardiovasc Pharmacol 1994; 24: 860–6
   PubMedGoogle Scholar
• Simon D I, Stamler J S, Jaraki O, et al. Antiplatelet properties of protein S-nitrosothiols derived from nitric oxide and endothelium-derived relaxing factor. Arterioscler Thromb 1993; 13: 791–9
   PubMedGoogle Scholar
• Gurdol F, Nwose O M, Mikhailidis D P. Gamma-glutamyl transferase activity in human platelets: quantification of activity, isoenzyme characterization and potential clinical relevance. Platelets 1995; 6: 200–3
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Shah M R, Pearce W H, Koch A E. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions 1994; 42: 159–62
   PubMedGoogle Scholar
• Lopes-Virella M F, Virella G. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 1992; 41(Suppl. 2)86–91
   PubMedGoogle Scholar
• Moyer C F, Sajuthi D, Tulli H, Williams J K. Synthesis of IL-1 alpha and IL-1 beta by arterial cells in atherosclerosis. Am J Pathol 1991; 138: 951–60
   PubMed Web of Science ®Google Scholar
• Heinrich J, Schulte H, Schonfeld R, Kohler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemostas 1995; 73: 374–9
   PubMed Web of Science ®Google Scholar
• Mori T, Sasaki J, Kawaguchi H, et al. Serum glycoproteins and severity of coronary atherosclerosis. Am Heart J 1995; 129: 234–8
   PubMed Web of Science ®Google Scholar
• Niewiarowski S. Secreted platelet proteins. Haemostasis and Thrombosis, 3rd edn., A L Bloom, C D Forbes, D P Thomas, E G D Tuddenham. Churchill Livingstone, Edinburgh 1994; 167–81
   Google Scholar
• Robson S C, Shephard E G, Kirsch R E. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, II-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol 1994; 86: 322–6
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H. FDP D-dimer induces the secretion of interleukin-I, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in a human promonocytic leukemia line. Blood 1991; 71: 94–100
   Google Scholar
• Soria C, Soria J, Collet J P, . Thrombotic disorder with decreased fibrinolysis related to fibrinogen abnormality. Fibrinogen a “New” Cardiovascular Risk Factor, E Ernst, W Koenig, G D O Lowe, T W. Made, et al. Blackwell-MZV, Vienna 1992; 315–20
   Google Scholar
• Slunga L, Asplund K, Johnson O, Dahlen G H. Lipoprotein (a) in a randomly selected 25–64 year old population: the Northern Sweden MONICA Study. J Clin Epidemiol 1993; 46: 617–24
   PubMed Web of Science ®Google Scholar
• Heinrich J, Sandkarnp M, Kokott R, Schulte H, Assmann G. Relationship of lipoprotein (a) to variables of coagulation and fibrinolysis in a healthy population. Clin Chem 1991; 37: 1950–4
   PubMed Web of Science ®Google Scholar
• Olofsson B O, Dahlen G H, Nilsson T K. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heqart J 1989; 10: 77–82
   PubMed Web of Science ®Google Scholar
• Ganotakis E S, Mikhailidis D P. Bezafibrate: treating hyperlipidemias as well as other cardiovascular risk factors. Today's Therap Trends 1996; 13: 231–49
   Google Scholar
• O'Brien R. Biological importance of low density lipoprotein subfractions. J Cardiovasc Risk 1994; 1: 207–11
   PubMedGoogle Scholar
• Halle M, Berg A, Keul J, Baumstark M W. Association between serum fibrinogen concentration and HDL and LDL subfraction phenotypes in healthy men. Arterioscl Thromb Vasc Biol 1996; 16: 144–8
   PubMedGoogle Scholar
• Glueck C J, Glueck H I, Tracy T, Speirs I, McCray C, Stroop D. Relationships between lipoprotein (a), lipids apolipoproteins, basal and stimulated fibrinolytic regulators, and D-dimers. Metabolism 1993; 42: 236–46
   PubMed Web of Science ®Google Scholar
• Mikhailidis D P, Barradas M A, Jeremy J Y, Winder A F. Platelets and lipoproteins. Platelets 1994; 5: 279
   PubMed Web of Science ®Google Scholar
• Heinrich J, Balleisen L, Schulte H, et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994; 14: 54–9, Correction: Arterioscler Thromb 1994; 14: 1392.
   PubMed Web of Science ®Google Scholar
• Meade T W, Vickers M V, Thompson S G, Stirling Y, Haines A P, Miller G J. Epidemiological characteristics of platelet aggregability. Br Med J 1985; 290: 428–32
   PubMed Web of Science ®Google Scholar
• Coumar A, Gill J K, Barradas M A, O'Donoghue S, Jeremy J Y, Mikhailidis D P. The effect of treatment with simvastatin on platelet function indices in hypercholesterolaemia. J Drug Develop 1991; 4: 79–86
   Google Scholar
• Pickart L. Increased ratio of plasma free fatty acids to albumin during normal aging and in patients with coronary heart disease. Atherosclerosis 1983; 46: 21–8
   PubMedGoogle Scholar
• Pickart L. Free fatty acidaemia as an inducer of systemic hyperfibrinogenemia and fibrinolytic inhibition. Inflammation 1981; 5: 61–70
   PubMedGoogle Scholar
• Pickart L, Thaler M M. Suppression of tumor-associated hyperfibrinogenemia and free fatty acidaemia with p-phenoxybenzalbutyrate (clofibrate). Cancer Res 1979; 39: 3845–8
   PubMedGoogle Scholar
• Pickart L. Fat metabolism, the fibrinogen/fibrinolytic system and blood flow: new potentials for the pharmacological treatment of coronary heart disease. Pharmacology 1981; 23: 271–80
   PubMedGoogle Scholar
• Ericsson C G, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849–53
   PubMed Web of Science ®Google Scholar
• de Faire U, Ericsson C G, Hamsten A, Nilsson J. Design features of a five-year bezafibrate coronary atherosclerosis intervention trial (BECAIT). Drugs Expert Clin Res 1995; 21: 105–124
   PubMedGoogle Scholar
• Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995; 15: 1263–8
   PubMedGoogle Scholar
• Tracy R P, Bovill E G, Yanez D, et al. Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1995; 15: 1269–79
   PubMedGoogle Scholar
• Woodburn K R, Lowe G D O, Rumley A, Love J, Pollock J G. Relation of haemostatic, fibrinolytic, and rheological variables to the angiographic extent of peripheral arterial occlusive disease. Int Angiol 1995; 14: 346–52
   PubMedGoogle Scholar